ANCA相关性血管炎患者临床特征及相关危险因素分析
Clinical Characteristics and Analysis of Risk Factors with ANCA-Associated Vasculitides
摘要: 目的:描述抗中性粒细胞胞浆抗体(antineutrophil cytoplasimc antibody, ANCA)相关血管炎(ANCA-associated vasculitis, AAV)患者的临床特征,分析影响生存率的相关危险性因素。方法:回顾分析了2010年至2019年在遂宁市中心医院新确诊为AAV患者的基本资料、临床特征、生存结局,并对相关危险因素进行统计学分析。结果:纳入AAV患者115例,显微镜下多血管炎(microscopic polyangiitis, MPA) 107例(93%),肉芽肿性多血管炎(granulomatosis with polyangiitis, GPA) 8例(7.0%),平均年龄63.7 ± 13.9 (14~89)岁,大于60岁的老年患者占72.2% (83例)。AAV相关症状发作到明确诊断的中位时间为4 (1~60)个月,平均BVAS为16.5 ± 6.7 (6~35)分,肾脏损害占86.1%,呼吸道损害占53.1%。死亡患者有46例,死亡原因为严重感染有25例(占54.3%),尿毒症并发症有7例(占15.2%),心血管不良事件有4件(占8.7%),血管炎活跃有6例(占13.0%),颅内出血有1例(占2.2%),不明原因有3例(占6.5%)。患者1年生存率为71.3%,5年生存率为60.8%。Kaplan-Meier生存曲线分析显示60岁以上患者生存率低(P = 0.042);血肌酐 > 400 umol/L的患者生存率低(P = 0.005);血小板计数 > 250 × 109/L患者的生存率低(P = 0.003)。进一步COX分析显示年龄(HR = 1.041, 95%CI = 1.014~1.068, P = 0.003)、血肌酐水平(HR = 1.085, 95%CI = 1.008~1.253, P = 0.002)、血小板(HR = 1.004, 95%CI = 1.001~1.007, P = 0.006)是影响患者生存率的独立危险因素。结论:老年人、血肌酐 > 400 umol/L、血小板 > 250 × 109/L是影响AAV患者生存率的独立危险因素。
Abstract: Objective: To describe the clinical characteristics of patients with antineutrophil cytoplasmic anti-body (ANCA)-associated vasculitis (ANCA-associated vasculitis, AAV), and analyze the related risk factors affecting survival. Methods: The basic data, clinical characteristics, and survival outcomes of patients newly diagnosed with AAV in Suining Central Hospital from 2010 to 2019 were retrospec-tively analyzed, and related risk factors were statistically analyzed. Results: A total of 115 patients with AAV were included, 107 patients (93%) with microscopic polyangiitis (MPA) and 8 patients (7.0%) with granulomatosis with polyangiitis (GPA), with an average age of 63.7 ± 13.9 (14~89) years old, and elderly patients over 60 years old accounted for 72.2% (83 cases). The median time from onset of AAV-related symptoms to definite diagnosis was 4 (1~60) months, the mean BVAS was 16.5 ± 6.7 (6~35) points, kidney damage accounted for 86.1%, and respiratory damage accounted for 53.1%. There were 46 deaths, among which 25 (54.3%) died of severe infection, 7 (15.2%) ure-mic complications, 4 (8.7%) adverse cardiovascular events, and 6 (13.0%) active vasculitis, 1 (2.2%) intracranial hemorrhage, and 3 (6.5%) cases of unknown cause. The 1-year survival rate was 71.3% and the 5-year survival rate was 60.8%. Kaplan-Meier survival curve analysis showed that the survival rate of patients over 60 years old was low (P = 0.042); the survival rate of patients with serum creatinine > 400 umol/L was low (P = 0.005); the survival rate of patients with platelet count > 250 × 109/L was low (P = 0.003). Further COX analysis showed that age (HR = 1.041, 95%CI = 1.014~1.068, P = 0.003), serum creatinine level (HR = 1.085, 95%CI = 1.008~1.253, P = 0.002), platelets (HR = 1.004, 95%CI = 1.001~1.007, P = 0.006) was an independent risk factor affecting the survival rate of patients. Conclusion: The elderly, serum creatinine > 400 umol/L, platelet > 250 × 109/L are independent risk factors affecting the survival rate of AAV patients.
文章引用:冉恩容, 王茂合, 刘蓉芝, 易艳霞. ANCA相关性血管炎患者临床特征及相关危险因素分析[J]. 临床医学进展, 2022, 12(6): 5974-5982. https://doi.org/10.12677/ACM.2022.126863

参考文献

[1] Pearce, F., Craven, A., Merkel, P., et al. (2017) Global Ethnic and Geographic Differences in the Clinical Presentations of Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis. Rheumatology, 56, 1962-1969. [Google Scholar] [CrossRef] [PubMed]
[2] Li, J., Cui, Z., Long, J.Y., et al. (2018) The Frequency of ANCA-Associated Vasculitis in a National Database of Hospitalized Patients in China. Arthritis Research & Therapy, 20, 226. [Google Scholar] [CrossRef] [PubMed]
[3] 张立民, 吴庆军, 冯胜, 等. 5种ANCA相关性血管炎活动性评分量表的比较[J]. 首都医科大学学报, 2010, 31(1): 103-105.
[4] Tedesco, M., Gallieni, M., Pellegata, F., et al. (2019) Update on ANCA-Associated Vasculitis: From Biomarkers to Therapy. Journal of Nephrology, 32, 871-882. [Google Scholar] [CrossRef] [PubMed]
[5] Hinojosa-Azaola, A. and Jiménez-González, A. (2017) Histopathologic Classification of Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis: Achievements, Limitations, and Perspectives. Clinical Rheumatology, 36, 1949-1957. [Google Scholar] [CrossRef] [PubMed]
[6] Chen, M., Yu, F., Zhang, Y., et al. (2005) Clinical and Patholog-ical Characteristics of Chinese Patients with Antineutrophil Cytoplasmic Autoantibody Associated Systemic Vasculitides: A Study of 426 Patients from a Single Centre. Postgraduate Medical Journal, 81, 723-727. [Google Scholar] [CrossRef] [PubMed]
[7] Wu, T., Zhong, Y., Zhou, Y., et al. (2020) Clinical Characteristics and Prognosis in 269 Patients with Antineutrophil Cytoplasimc Antibody Associated Vasculitis. Journal of Central South University. Medical Sciences, 45, 916-922.
[8] Shuai, Z.W., Lv, Y.F., Zhang, M.M., et al. (2015) Clinical Anal-ysis of Patients with Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Genetics and Molec-ular Research, 14, 5296-5303. [Google Scholar] [CrossRef
[9] Homma, S., Suzuki, A. and Sato, K. (2013) Pulmonary Involvement in ANCA-Associated Vasculitis from the View of the Pulmonologist. Clinical and Experimental Nephrology, 17, 667-671. [Google Scholar] [CrossRef] [PubMed]
[10] Hasegawa, M., Hattori, K., Sugiyama, S., et al. (2016) A Retrospective Study on the Outcomes of MPO-ANCA-Associated Vasculitis in Dialysis-Dependent Patients. Modern Rheumatology, 26, 110-114. [Google Scholar] [CrossRef] [PubMed]
[11] Walton, E. (1958) Giant-Cell Granuloma of the Respiratory Tract (Wegener’s Granulomatosis). British Medical Journal, 2, 265-270. [Google Scholar] [CrossRef] [PubMed]
[12] Semple, J., Italiano, J. and Freedman, J. (2011) Platelets and the Im-mune Continuum. Nature Reviews Immunology, 11, 264-274. [Google Scholar] [CrossRef] [PubMed]
[13] Willeke, P., Kumpers, P., Schluter, B., et al. (2015) Platelet Counts as a Biomarker in ANCA-Associated Vasculitis. Scandinavian Journal of Rheumatology, 44, 302-308. [Google Scholar] [CrossRef] [PubMed]
[14] Fauci, A.S., Haynes, B.F., Katz, P., et al. (1983) Wegener’s Granulomatosis: Prospective Clinical and Therapeutic Experience with 85 Patients for 21 Years. Annals of Internal Medicine, 98, 76-85. [Google Scholar] [CrossRef] [PubMed]
[15] Hoffman, G.S., Kerr, G.S., Leavitt, R.Y., et al. (1992) Wegener Granulomatosis: An Analysis of 158 Patients. Annals of Internal Medicine, 116, 488-498. [Google Scholar] [CrossRef] [PubMed]
[16] Huang, L., Zhong, Y., Ooi, J.D., et al. (2019) The Effect of Pulse Methylprednisolone Induction Therapy in Chinese Patients with Dialysis-Dependent MPO-ANCA Associated Vasculitis. International Immunopharmacology, 76, Article ID: 105883. [Google Scholar] [CrossRef] [PubMed]
[17] Yang, L., Xie, H., Liu, Z., et al. (2018) Risk Factors for Infec-tious Complications of ANCA-Associated Vasculitis: A Cohort Study. BMC Nephrology, 19, Article No. 138. [Google Scholar] [CrossRef] [PubMed]
[18] Kronbichler, A., Kerschbaum, J., Gopaluni, S., et al. (2018) Tri-methoprim-Sulfamethoxazole Prophylaxis Prevents Severe/Life-Threatening Infections Following Rituximab in Antineu-trophil Cytoplasm Antibody-Associated Vasculitis. Annals of the Rheumatic Diseases, 77, 1440-1447. [Google Scholar] [CrossRef] [PubMed]
[19] Casal Moura M, Irazabal M, Eirin A, et al. (2020) Effica-cy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Renal Disease. Journal of the American Society of Nephrology: JASN, 31, 2688-2704. [Google Scholar] [CrossRef
[20] Novikov, P., Bulanov, N., Zykova, A., et al. (2020) Prevention of Infections in Patients with Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Potential Role of Hydroxychloro-quine. Annals of the Rheumatic Diseases, 79, e19. [Google Scholar] [CrossRef] [PubMed]